Synta Rises on Potential for Novel Cancer Drug: Boston Mover
This article is for subscribers only.
Synta Pharmaceuticals Corp. gained the most in 20 months in anticipation of study results that may help pave the way for broader use of its experimental lung cancer compound ganetespib.
Synta rose 16 percent to $4.81 at the close in New York, the biggest increase since September 2010. Interim results of the study should be released by Lexington, Massachusetts-based Synta in June, Thomas Wei, an analyst at Jefferies & Co. in New York, said yesterday in a note to clients.